首页> 外文期刊>The Journal of Immunology: Official Journal of the American Association of Immunologists >Molecular Mechanisms of Cytokine and Chemokine Release from Eosinophils Activated by IL-17A, IL-17F, and IL-23: Implication for Th17 Lymphocytes-Mediated Allergic Inflammation.
【24h】

Molecular Mechanisms of Cytokine and Chemokine Release from Eosinophils Activated by IL-17A, IL-17F, and IL-23: Implication for Th17 Lymphocytes-Mediated Allergic Inflammation.

机译:IL-17A,IL-17F和IL-23激活的嗜酸性粒细胞释放细胞因子和趋化因子的分子机制:对Th17淋巴细胞介导的过敏性炎症的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

IL-17A and IL-17F are members of the IL-17 family that play crucial roles in allergic inflammation. Recent studies reported that IL-17A and IL-17F production from a distinct Th lymphocyte subset, Th17, was specifically induced by IL-23, which was produced by dendritic cells and macrophages in response to microbial stimuli. The IL-23-IL-17 axis might therefore provide a link between infections and allergic diseases. In the present study, we investigated the effects of IL-17A, IL-17F, and IL-23, alone or in combination, on cytokine and chemokine release from eosinophils and the underlying intracellular mechanisms. Human eosinophils were found to constitutively express receptors for IL-17A, IL-17F, and IL-23 at the protein level. IL-17A, IL-17F, and IL-23 could induce the release of chemokines GRO-alpha/CXCL1, IL-8/CXCL8, and MIP-1beta/CCL4 from eosinophils, while IL-17F and IL-23 could also increase the production of proinflammatory cytokines IL-1beta and IL-6. Synergistic effects were observed in the combined treatment of IL-17F and IL-23 on the release of proinflammatory cytokines, and the effects were dose-dependently enhanced by IL-23, but not IL-17F. Further investigations showed that IL-17A, IL-17F, and IL-23 differentially activated the ERK, p38 MAPK, and NF-kappaB pathways. Moreover, inhibition of these pathways using selective inhibitors could significantly abolish the chemokine release induced by IL-17A, IL-17F, and IL-23 and the synergistic increases on IL-1beta and IL-6 production mediated by combined treatment of IL-17F and IL-23. Taken together, our findings provide insight for the Th17 lymphocyte-mediated activation of eosinophils via differential intracellular signaling cascades in allergic inflammation.
机译:IL-17A和IL-17F是IL-17家族的成员,在过敏性炎症中起关键作用。最近的研究报道,IL-23特异性地诱导了来自不同的Th淋巴细胞亚群Th17的IL-17A和IL-17F的产生,IL-23是由树突状细胞和巨噬细胞响应微生物刺激而产生的。因此,IL-23-IL-17轴可能提供了感染和过敏性疾病之间的联系。在本研究中,我们研究了IL-17A,IL-17F和IL-23单独或组合对嗜酸性粒细胞释放的细胞因子和趋化因子的作用以及潜在的细胞内机制。发现人嗜酸性粒细胞在蛋白质水平上组成性表达IL-17A,IL-17F和IL-23的受体。 IL-17A,IL-17F和IL-23可以诱导嗜酸性粒细胞释放趋化因子GRO-alpha / CXCL1,IL-8 / CXCL8和MIP-1beta / CCL4,而IL-17F和IL-23也可以增加促炎细胞因子IL-1beta和IL-6的产生。 IL-17F和IL-23联合治疗对促炎细胞因子的释放具有协同作用,并且IL-23而非IL-17F剂量依赖性地增强了这种作用。进一步的研究表明,IL-17A,IL-17F和IL-23差异激活了ERK,p38 MAPK和NF-κB途径。此外,使用选择性抑制剂抑制这些途径可显着消除IL-17A,IL-17F和IL-23诱导的趋化因子释放,以及联合治疗IL-17F介导的IL-1beta和IL-6产生的协同增加和IL-23。综上所述,我们的发现为过敏性炎症中Th17淋巴细胞介导的嗜酸性粒细胞活化通过不同的细胞内信号级联反应提供了见识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号